|Bid||9.55 x 2200|
|Ask||9.70 x 800|
|Day's range||9.15 - 9.78|
|52-week range||5.27 - 18.50|
|Beta (3Y monthly)||1.23|
|PE ratio (TTM)||N/A|
|Earnings date||25 Feb 2019 - 1 Mar 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||16.61|
Members of the wealthy Sackler family behind Purdue Pharma LP personally pushed the company to boost sales of OxyContin and other opioid products even as questions emerged about the extent its painkillers were being abused, Massachusetts' attorney general alleged on Tuesday. Attorney General Maura Healey filed an amended lawsuit against Purdue and current and former officers and directors of the drugmaker that drew on internal records to reveal new details about family's involvement in the company.
Heron (HRTX) soars after the FDA accepted the company's NDA for pain drug, HTX-011, and granted Priority Review designation to the application.
Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it has signed a Definitive Agreement with Endo International plc's (ENDP) subsidiary, Endo Ventures Limited, for the further development and commercialization of generic Sabril® (vigabatrin) tablets through Endo’s U.S. Generic Pharmaceuticals segment, doing business as Par Pharmaceutical. Pursuant to the agreement, Catalyst will receive an up-front payment, milestone payments based on achievement of regulatory approvals, and a sharing of defined net profits upon commercialization.
Endo International shares slid 8 percent as a '60 Minutes' report on data collected by opioid distributors regarding the amounts and destinations of painkillers is set to air Sunday.
In December 2018, of the total 16 analysts covering Endo International (ENDP), five analysts have given Endo stock a “buy” or higher rating and 11 analysts have given it a “hold” rating. The mean rating for Endo International stock is 2.5 with a target price of $17.04, implying an upside potential of 47.3% over Endo International’s closing price of $11.57 on December 7, 2018.
How's Endo International Positioned in December? Endo International (ENDP) incurred net interest expenses of $131.85 million in the third quarter of 2018 as compared with $127.52 million in the year-ago period. Endo International’s net loss per share was $0.43 in the third quarter of 2017.
Endo International’s (ENDP) next two business segments are: The US Generic Pharmaceuticals segment includes solid oral extended release, solid oral immediate release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, and sprays. Revenues from this segment declined from $294.75 million in the third quarter of 2017 to $257.97 million in the third quarter of 2018. The International Pharmaceuticals segment revenues also declined from $56.43 million in the third quarter of 2017 to $30.25 million in the third quarter of 2018.
How's Endo International Positioned in December? For fiscal 2018 and 2019, Endo is expected to incur research and development expenses of $162.01 million and $165.43 million, respectively. Endo expects its US generic pharmaceuticals research and development costs to decline due to its moving its R&D activities to India.
How's Endo International Positioned in December? Endo International (ENDP) is a global specialty pharmaceutical company with a focus on generic and branded pharmaceuticals. Endo International generated total revenues of $745.47 million in the third quarter of 2018 as compared with $786.89 million in the comparable period of 2017.
NEW YORK, Dec. 04, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Bausch Health’s (BHC) wholly owned subsidiary Salix Pharmaceuticals generated revenues of $460.0 million in the third quarter compared to $452.0 million in the third quarter of 2017, reflecting ~2% YoY growth. Xifaxan and Relistor primarily contributed to the revenue growth of Salix Pharmaceuticals in the third quarter. In the third quarter, Xifaxan and Relistor witnessed ~11% and 88% YoY organic revenue growth.
On November 13, Bausch Health stock closed at $26.63, which is a ~1.60% increase from its prior close of $26.21 on November 12, 2018. On November 13, Bausch Health stock closed at $26.63, a ~92% increase from its 52-week low of $13.86 on November 15, 2017. On October 3, 2018, Bausch Health hit its 52-week high of $28.45.
This mutual fund is focused on small-cap stocks, and the fund's managers like the outlook for small caps.
The best pharmaceutical stocks to buy have a commonality: Strong Composite Ratings and Relative Strength Ratings.
On its third-quarter earnings conference call, Endo International (ENDP) raised its projection for operating expenses as a percentage of its total revenue guidance for 2018 from its previously projected range of 26.0%–27.0% to 27.0%.
On its third-quarter earnings conference call, Endo International (ENDP) raised its revenue guidance for 2018 from the previously projected range of $2.75 billion–$2.85 billion to $2.87 billion–$2.92 billion mainly due to its stronger-than-anticipated performance YTD (year-to-date).
The stock was trading 22.77% lower than its closing price of $17.08 on November 1. It closed at $13.49 on November 9, 2.27% higher than its previous closing price. Endo International reported its third-quarter earnings results on November 8.
Endo (ENDP) tops revenues and earnings expectations in the third quarter and raises its annual view. However, the results from the cellulite treatment trial are disappointing.
Endo International stock crashed Thursday despite beating quarterly expectations as the generic drugmaker reportedly plans to launch its cellulite treatment in 2020.